| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(02)11198-6 |
| P698 | PubMed publication ID | 12387962 |
| P50 | author | Kevin Marsh | Q30102986 |
| P2093 | author name string | C V Plowe | |
| M E Molyneux | |||
| W M Watkins | |||
| J G Kublin | |||
| T E Taylor | |||
| P A Winstanley | |||
| P Chimpeni | |||
| J Hatcher | |||
| J Sulo | |||
| P2860 | cites work | Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum | Q31389858 |
| Chemotherapy for falciparum malaria: the armoury, the problems and the prospects | Q33868231 | ||
| Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. | Q34743292 | ||
| Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine | Q35121790 | ||
| Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance | Q37739332 | ||
| Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine | Q38345011 | ||
| Cost-effectiveness of malaria control in sub-Saharan Africa. | Q39028600 | ||
| Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. | Q39113802 | ||
| Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. | Q39557015 | ||
| In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs | Q39779567 | ||
| The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses | Q41913682 | ||
| Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania | Q41918630 | ||
| Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. | Q41923590 | ||
| Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. | Q41934737 | ||
| Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria | Q43864384 | ||
| Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania | Q43949629 | ||
| Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life | Q44012338 | ||
| Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range | Q46154949 | ||
| Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance | Q46878245 | ||
| Cardiac effects of antimalarial treatment with halofantrine | Q48013877 | ||
| P433 | issue | 9340 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Kenya | Q114 |
| Malawi | Q1020 | ||
| malaria | Q12156 | ||
| Plasmodium falciparum | Q311383 | ||
| pyrimethamine | Q421072 | ||
| P304 | page(s) | 1136-1143 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial | |
| P478 | volume | 360 |
| Q35541786 | Antimalarial compounds: from bench to bedside |
| Q39149127 | Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response |
| Q34780397 | Challenges Associated with Scaling up Artemisinin Combination Therapy in Sub-Saharan Africa A Review Article |
| Q28548617 | Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control |
| Q37223629 | Chloroquine resistance before and after its withdrawal in Kenya |
| Q24245853 | Chlorproguanil-dapsone for treating uncomplicated malaria |
| Q38870092 | Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial |
| Q35824695 | Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes |
| Q37488734 | Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. |
| Q43452416 | Effect of artesunate plus sulfadoxine-pyrimethamine on haematological recovery and anaemia, in Kenyan children with uncomplicated, Plasmodium falciparum malaria |
| Q34085681 | Elevated plasma von Willebrand factor and propeptide levels in Malawian children with malaria |
| Q36104143 | Exploring the folate pathway in Plasmodium falciparum |
| Q28478215 | Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum |
| Q28474365 | High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency |
| Q36736817 | In-vivo parasitological response to sulfadoxine-pyrimethamine in pregnant women in southern Malawi |
| Q35652102 | Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed? |
| Q28473566 | Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial |
| Q56341579 | Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients |
| Q39683615 | Knowledge, attitudes and practices towards malaria among primary school pupils in Ndirande, Blantyre, Malawi |
| Q36955257 | Malaria research and its influence on anti-malarial drug policy in Malawi: a case study |
| Q37349030 | Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi |
| Q35541782 | Monitoring antimalarial drug resistance: making the most of the tools at hand |
| Q33935361 | Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi |
| Q28472247 | Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria |
| Q45973898 | Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. |
| Q41942143 | Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance |
| Q53701213 | Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. |
| Q35031434 | Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia |
| Q35850290 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants |
| Q35147242 | Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa |
| Q46501353 | Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Authors' reply |
| Q46594461 | The Interaction between HIV and malaria in Africa |
| Q36947762 | The anatomy of a malaria disaster: drug policy choice and mortality in African children |
| Q28180054 | The development of Lapdap, an affordable new treatment for malaria |
| Q28286833 | The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics |
| Q39546704 | Treating malaria in pregnancy in developing countries: priorities in clinical research and drug development |
| Q48036116 | Treatment and prevention of malaria in pregnancy: opportunities and challenges. |
Search more.